Liquidia Corp (LQDA) Stock Price, Quote & News

Latest News on LQDA

May 12, 2025, 6:00 AM EDT - 2 days ago

Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics

May 10, 2025, 9:29 PM EDT - 3 days ago

Liquidia Corporation (LQDA) Q1 2025 Earnings Call Transcript

May 8, 2025, 6:30 AM EDT - 6 days ago

Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 5, 2025, 4:06 PM EDT - 8 days ago

Liquidia Corporation: A Strong Buy On High Likelihood Of FDA Approval This Month

May 2, 2025, 5:28 PM EDT - 11 days ago

District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia

May 1, 2025, 8:00 AM EDT - 13 days ago

Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 30, 2025, 9:30 AM EDT - 14 days ago

Arquitos Capital's Largest Holdings For Q1 2025

Apr 1, 2025, 10:33 AM EDT - 6 weeks ago

UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 8:00 AM EDT - 6 weeks ago

Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 28, 2025, 9:30 AM EDT - 6 weeks ago

Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder

Mar 19, 2025, 11:56 AM EDT - 2 months ago

Liquidia Corporation (LQDA) Q4 2024 Earnings Call Transcript

Mar 19, 2025, 6:30 AM EDT - 2 months ago

Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 12, 2025, 8:00 AM EDT - 2 months ago

Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025

Nov 15, 2024, 10:20 AM EST - 6 months ago

Liquidia Corporation: Resilience In The Face Of Formidable Opposition Can Pay Off

Nov 13, 2024, 2:40 PM EST - 6 months ago

Liquidia Corporation (LQDA) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 6:30 AM EST - 6 months ago

Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 7, 2024, 10:00 AM EDT - 7 months ago

United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics' Patent

Oct 2, 2024, 6:00 AM EDT - 8 months ago

Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)

Oct 1, 2024, 11:00 AM EDT - 8 months ago

Liquidia Corporation Is Being Sued For Violating Securities Laws And Affected Investors Are Invited To Help The Schall Law Firm

Sep 30, 2024, 11:00 AM EDT - 8 months ago

Liquidia Corporation Is Being Investigated For Violating Securities Laws And Impacted Investors Are Encouraged To Contact The Schall Law Firm

Sep 30, 2024, 8:00 AM EDT - 8 months ago

Liquidia Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting

Sep 29, 2024, 11:00 AM EDT - 8 months ago

The Schall Law Firm Urges Shareholder Participation In A Securities Fraud Inquiry Into Liquidia Corporation

Sep 28, 2024, 11:00 AM EDT - 8 months ago

Liquidia Corporation Is Being Investigated For Violating Securities Laws And Investors Are Invited To Contact The Schall Law Firm

Sep 24, 2024, 11:00 AM EDT - 8 months ago

Investors Are Invited To Help The Schall Law Firm Investigate Whether Liquidia Corporation Violated Securities Laws

Sep 23, 2024, 11:00 AM EDT - 8 months ago

The Schall Law Firm Is Looking Into Liquidia Corporation For Securities Fraud And Shareholders With Losses Should Reach Out

Sep 21, 2024, 11:00 AM EDT - 8 months ago

Liquidia Corporation May Have Defrauded The Public And The Schall Law Firm Wants Shareholders With Losses To Reach Out

Sep 20, 2024, 11:00 AM EDT - 8 months ago

The Schall Law Firm Has Launched An Inquiry Into Liquidia Corporation For Violating Securities Laws And Affected Investors Should Participate

Sep 19, 2024, 11:00 AM EDT - 8 months ago

Liquidia Corporation Is Being Investigated For Securities Fraud And Shareholders With Losses Are Urged To Reach Out To The Schall Law Firm

Sep 18, 2024, 11:00 AM EDT - 8 months ago

The Schall Law Firm Invites Investors To Join An Inquiry Into Liquidia Corporation For Violating Securities Laws

Sep 17, 2024, 11:00 AM EDT - 8 months ago

Liquidia Corporation Is Being Investigated For Securities Fraud And Affected Stakeholders Are Urged To Reach Out To The Schall Law Firm

Sep 16, 2024, 9:41 AM EDT - 8 months ago

Court Finds United Therapeutics' Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million

Sep 15, 2024, 11:00 AM EDT - 8 months ago

Liquidia Corporation May Have Engaged In Securities Fraud And Investors Are Urged To Join The Schall Law Firm's Investigation

Sep 14, 2024, 11:00 AM EDT - 8 months ago

The Schall Law Firm Is Inquiring Into Liquidia Corporation's Questionable Practices And Shareholders Should Reach Out

Sep 13, 2024, 11:00 AM EDT - 8 months ago

Liquidia Corporation May Have Violated Securities Regulations And The Schall Law Firm Urges Investors To Partake In An Investigation

Sep 12, 2024, 11:00 AM EDT - 8 months ago

The Schall Law Firm Is Looking Into Whether Liquidia Corporation Engaged In Securities Fraud And Affected Shareholders Can Lend A Hand

Sep 11, 2024, 8:26 AM EDT - 8 months ago

Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement

Sep 10, 2024, 11:00 AM EDT - 8 months ago

Liquidia Corporation May Have Committed Securities Fraud And The Schall Law Firm Encourages Shareholders To Assist With An Investigation

Sep 10, 2024, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Liquidia Technologies, Inc.(LQDA) and Encourages Shareholders to Learn More About the Investigation

Market Cap	1.35B
Revenue (ttm)	14.00M
Net Income (ttm)	-130.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-931.36%
Debt to Equity Ratio	1.49

Volume	884,000
Avg Vol	1,174,676
Day's Range	N/A - N/A
Shares Out	85.49M
Stochastic %K	66%
Beta	0.24
Analysts	Strong Sell
Price Target	$27.22